Compare Aurobindo Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PFIZER - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PFIZER AUROBINDO PHARMA/
PFIZER
 
P/E (TTM) x 11.0 32.7 33.6% View Chart
P/BV x 2.4 5.5 43.5% View Chart
Dividend Yield % 0.5 0.6 84.4%  

Financials

 AUROBINDO PHARMA   PFIZER
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
PFIZER
Mar-18
AUROBINDO PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs8092,365 34.2%   
Low Rs5041,625 31.0%   
Sales per share (Unadj.) Rs281.1430.3 65.3%  
Earnings per share (Unadj.) Rs41.478.7 52.5%  
Cash flow per share (Unadj.) Rs50.993.2 54.6%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.41.0 38.0%  
Book value per share (Unadj.) Rs199.4586.5 34.0%  
Shares outstanding (eoy) m585.8845.75 1,280.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.6 50.4%   
Avg P/E ratio x15.925.3 62.6%  
P/CF ratio (eoy) x12.921.4 60.3%  
Price / Book Value ratio x3.33.4 96.8%  
Dividend payout %6.025.4 23.8%   
Avg Mkt Cap Rs m384,63091,271 421.4%   
No. of employees `00017.32.6 659.0%   
Total wages/salary Rs m21,3083,143 678.0%   
Avg. sales/employee Rs Th9,500.77,484.8 126.9%   
Avg. wages/employee Rs Th1,229.41,195.0 102.9%   
Avg. net profit/employee Rs Th1,397.91,369.1 102.1%   
INCOME DATA
Net Sales Rs m164,66619,685 836.5%  
Other income Rs m1,0201,143 89.2%   
Total revenues Rs m165,68620,828 795.5%   
Gross profit Rs m37,7185,003 753.9%  
Depreciation Rs m5,580663 842.2%   
Interest Rs m7774 18,504.8%   
Profit before tax Rs m32,3805,479 591.0%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,878 435.6%   
Profit after tax Rs m24,2293,601 672.9%  
Gross profit margin %22.925.4 90.1%  
Effective tax rate %25.334.3 73.7%   
Net profit margin %14.718.3 80.4%  
BALANCE SHEET DATA
Current assets Rs m121,87824,167 504.3%   
Current liabilities Rs m86,8069,544 909.5%   
Net working cap to sales %21.374.3 28.7%  
Current ratio x1.42.5 55.4%  
Inventory Days Days13055 235.8%  
Debtors Days Days6829 238.2%  
Net fixed assets Rs m81,0379,514 851.8%   
Share capital Rs m586458 128.1%   
"Free" reserves Rs m116,21826,375 440.6%   
Net worth Rs m116,80426,832 435.3%   
Long term debt Rs m4,51225 18,048.0%   
Total assets Rs m211,05236,900 572.0%  
Interest coverage x42.71,305.5 3.3%   
Debt to equity ratio x00 4,145.9%  
Sales to assets ratio x0.80.5 146.3%   
Return on assets %11.89.8 121.3%  
Return on equity %20.713.4 154.6%  
Return on capital %27.420.4 134.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72722 360,389.3%   
Fx outflow Rs m34,7001,489 2,330.9%   
Net fx Rs m46,027-1,466 -3,139.0%   
CASH FLOW
From Operations Rs m19,5483,318 589.2%  
From Investments Rs m-19,570-2,383 821.2%  
From Financial Activity Rs m8,642-1,104 -783.1%  
Net Cashflow Rs m8,922-169 -5,295.0%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.0 7.5 106.0%  
FIIs % 27.7 4.9 565.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 23.7 43.0%  
Shareholders   69,601 85,207 81.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON   J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 18, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS